Ralmitaront Explained

Ralmitaront (; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which is undergoing a clinical trial for the treatment of negative symptoms in schizophrenia and schizoaffective disorder.[1] [2] Another clinical trial targeting acute psychotic symptoms of schizophrenia has been terminated due to lack of efficacy. It is a partial agonist of the TAAR1.[3] The medication is being developed by the pharmaceutical company Hoffmann-La Roche. Ralmitaront had completed phase 1 clinical trials.

See also

Notes and References

  1. Web site: Ralmitaront - Roche . AdisInsight . Springer Nature Switzerland AG .
  2. Gomes FV, Grace AA . Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention . International Journal of Molecular Sciences . 22 . 9 . April 2021 . 4467 . 33922888 . 8123139 . 10.3390/ijms22094467 . free .
  3. Web site: Ralmitaront: Relationships: Trace Amine-Associated Receptor 1 . Global Substance Registration System (GSRS) . U.S. Food and Drug Administration .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ralmitaront".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.